Equities researchers at HC Wainwright started coverage on shares of Aratana Therapeutics (NASDAQ:PETX) in a report released on Friday, November 17th, Marketbeat.com reports. The firm set a “buy” rating and a $10.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price target would suggest a potential upside of 90.11% from the stock’s previous close.
Several other equities research analysts have also issued reports on PETX. ValuEngine lowered shares of Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. BidaskClub lowered shares of Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 8th. Lake Street Capital lowered their price target on shares of Aratana Therapeutics from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, August 25th. Jefferies Group set a $8.00 price target on shares of Aratana Therapeutics and gave the company a “buy” rating in a report on Friday, August 4th. Finally, Zacks Investment Research raised shares of Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $7.75 price target on the stock in a report on Thursday, November 9th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $8.75.
Shares of Aratana Therapeutics (NASDAQ PETX) traded down $0.19 during mid-day trading on Friday, reaching $5.26. 706,743 shares of the company were exchanged, compared to its average volume of 416,079. Aratana Therapeutics has a fifty-two week low of $4.97 and a fifty-two week high of $8.63. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.08 and a current ratio of 3.42.
Aratana Therapeutics (NASDAQ:PETX) last announced its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.24) by $0.03. The firm had revenue of $6.16 million for the quarter, compared to analyst estimates of $6.47 million. Aratana Therapeutics had a negative net margin of 358.55% and a negative return on equity of 48.79%. The business’s revenue for the quarter was up 1440.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.38) EPS. analysts predict that Aratana Therapeutics will post -1.03 EPS for the current year.
In other news, insider Peter Steven St sold 50,000 shares of the business’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $6.24, for a total value of $312,000.00. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Ernst Heinen sold 10,000 shares of the business’s stock in a transaction on Friday, September 15th. The shares were sold at an average price of $6.25, for a total transaction of $62,500.00. Following the completion of the sale, the insider now owns 130,994 shares in the company, valued at approximately $818,712.50. The disclosure for this sale can be found here. Insiders sold a total of 1,127,032 shares of company stock worth $6,622,391 in the last 90 days. 5.20% of the stock is owned by corporate insiders.
Several large investors have recently modified their holdings of PETX. Janus Henderson Group PLC acquired a new stake in shares of Aratana Therapeutics in the 2nd quarter valued at $12,948,000. Broadfin Capital LLC lifted its position in Aratana Therapeutics by 40.3% during the 2nd quarter. Broadfin Capital LLC now owns 5,184,942 shares of the biopharmaceutical company’s stock worth $37,487,000 after buying an additional 1,489,500 shares in the last quarter. Franklin Resources Inc. lifted its position in Aratana Therapeutics by 11.2% during the 2nd quarter. Franklin Resources Inc. now owns 6,011,309 shares of the biopharmaceutical company’s stock worth $43,462,000 after buying an additional 604,518 shares in the last quarter. AWM Investment Company Inc. lifted its position in Aratana Therapeutics by 49.4% during the 2nd quarter. AWM Investment Company Inc. now owns 1,587,620 shares of the biopharmaceutical company’s stock worth $11,478,000 after buying an additional 525,000 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in Aratana Therapeutics by 197.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 380,895 shares of the biopharmaceutical company’s stock worth $2,754,000 after buying an additional 252,655 shares in the last quarter. Institutional investors own 73.95% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://www.dispatchtribunal.com/2017/12/04/aratana-therapeutics-inc-petx-coverage-initiated-at-hc-wainwright.html.
About Aratana Therapeutics
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.